Indivior Pharmaceuticals, Inc. INDV 深 沪
已收盘 04-02 16:00:00 美东时间
30.47
-0.180
-0.59%
华盛通- 最 高30.565
- 今 开29.99
- 成交量 214.75万股
- 最 低 29.65
- 昨 收 30.65
- 总市值 37.15亿
- 52周最高 38.00
- 市盈率 静 18.57
- 换手率 1.76%
- 52周最低 8.69
- 委 比 47.26%
- 总股本 1.22亿
- 历史最高 38.00
- 量 比 1.13
- 振 幅 2.99%
- 历史最低 7.33
- 每 手 1
- 风险率 9.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Indivior Announces Findings From Retrospective Observational Study Showing Adherence To SUBLOCADE Monthly Injectable Buprenorphine Linked To Lower Healthcare Utilization And Costs In Opioid Use Disorder
Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency department, and
03-11 21:04
财报速睇 | Indivior Pharmaceuticals, Inc. 2025财年年度营收12.39亿美元，同比增长4.3%；归母净利润2.10亿美元，同比增长2900.0%
华盛资讯2月27日讯，Indivior Pharmaceuticals, Inc.公布2025财年年度业绩，公司年度营收12.39亿美元，同比增长4.3%，归母净利润2.10亿美元，同比增长2900.0%。
02-27 05:51
财报速睇 | Indivior Pharmaceuticals, Inc. 2025财年Q4营收3.58亿美元，同比增长20.1%；归母净利润1.02亿美元，同比增长385.7%
华盛资讯2月26日讯，Indivior Pharmaceuticals, Inc.公布2025财年Q4业绩，公司Q4营收3.58亿美元，同比增长20.1%，归母净利润1.02亿美元，同比增长385.7%。
02-26 21:46
财报速睇 | Indivior Pharmaceuticals, Inc. 2025财年Q4营收3.58亿美元，同比增长20.1%；归母净利润1.02亿美元，同比增长385.7%
华盛资讯2月26日讯，Indivior Pharmaceuticals, Inc.公布2025财年Q4业绩，公司Q4营收3.58亿美元，同比增长20.1%，归母净利润1.02亿美元，同比增长385.7%。
02-26 21:35
Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, becoming a Delaware corporation. The former Indivior PLC is now Indivior Ltd., a wholly-owned subsidiary. Its shares are listed on Nasdaq under "INDV." The move aims to strengthen US market presence, enhance equity index inclusion, simplify governance, and bolster its position as a US-based innovation leader in treating opioid use disorder.
01-26 12:00
'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks
Kevin Mahn highlighted the potential impact of the recent tariff noise on the market and advised investors to look beyond the headlines.
01-21 17:54
Trump admin rolls back $2B in mental health, addiction grant cuts—report
The Trump administration is rolling back $2B in cuts to mental health and addiction programs, NPR reported, citing a Trump administration official. Letters restoring the funding are expected to be sen...
01-15 19:49
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48
HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $35 to $48.
01-12 19:18
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Indivior PLC announced its 2026 financial guidance with total net revenue expected between $1.125 billion and $1.195 billion, and SUBLOCADE® net revenue projected at $905 million to $945 million. Non-GAAP operating expenses are forecasted at $430 million to $450 million, while adjusted EBITDA is anticipated to range from $535 million to $575 million. The company has completed Phase I of its Indivior Action Agenda, focusing on growing SUBLOCADE re...
01-08 12:00
